Following on from Scott, there's a good chance further efficacy, biomarker and safety data will be presented this weekend at American Academy of Neurology Conference in California. The abstract poster posted couple months ago states this updated data will be available in Q1 2025, and it'll be presented at this conference. Here is that abstract https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-005685.html.
The fact we already know this data will show 434 is safe and gives stat. sig clinical benefit vs placebo gives me some reassurance we shouldn't have a OPT or PER disaster on our hands, but having lost out on PER I can see why some people might want to sell-off some of their holdings coming into results if SP has already appreciated. Also perhaps this seller doesn't agree with yesterday's vote and in-coming dilution.. Cheers
ATH Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)